Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10761583 | 0.92 | HTR2C (0.49) | HTR2CHTR2AHTR2BDRD2CA12 | |
| SCHEMBL18555663 | 0.84 | KDM4E (0.41) | MEN1KMT2ACYP19A1 | |
| SCHEMBL9826178 | 0.81 | HTR2C (0.46) | HTR2CHTR2AHTR2BDRD2CA12 | |
| SCHEMBL13381007 | 0.80 | HTR2C (0.45) | HTR2CHTR2AHTR2BDRD2CA12 | |
| SCHEMBL11629567 | 0.79 | HTR2C (0.44) | HTR2CHTR2AHTR2BDRD2CA12 | |
| SCHEMBL30949067 | 0.79 | HTR2C (0.47) | HTR2CHTR2AHTR2BDRD2MEN1 | |
| SCHEMBL28230707 | 0.77 | MEN1 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL13381250 | 0.76 | DRD2 (0.46) | HTR2CHTR2AHTR2BDRD2MEN1 | |
| SCHEMBL3686228 | 0.76 | KMT2A (0.45) | MEN1KMT2A | |
| SCHEMBL13381276 | 0.76 | CYP19A1 (0.43) | HTR2CHTR2AHTR2BDRD2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663974-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | AstraZeneca AB (SE) | 2006-06-07 | — | — | EP | disclosed |
| EP-1615890-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089903-A9 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER LAMBERT CO (US) | 2005-10-27 | — | — | WO | disclosed |
| WO-2005026124-A1 | 2-PYRIDONE DERIVATIVES AS NETROPHIL ELASTASE INHIBITORS AND THEIR USE | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089915-A1 | PIPERAZINE DERIVATIVE RENIN INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089903-A1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | WARNER-LAMBERT COMPANY LLC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-14 | — | — | US | disclosed |
| EP-0304138-B1 | PROCESS FOR MAKING 1,3-DIOXANE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-03-04 | — | — | EP | disclosed |
| US-5063197-A | Aromatic compound | MITSUBISHI PAPER MILLS LIMITED (JP) | 1991-11-05 | — | — | US | disclosed |
| EP-0304139-B1 | PROCESS FOR MAKING 5-HYDROXY-3-HYDROXYMETHYL-2-PHENYLFURAN DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1991-09-11 | — | — | EP | disclosed |
| EP-0201351-B1 | 1,3-DIOXANE ETHERS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1990-11-07 | — | — | EP | disclosed |
| EP-0304139-A1 | Process for making 5-hydroxy-3-hydroxymethyl-2-phenylfuran derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-02-22 | — | — | EP | disclosed |
| EP-0304138-A1 | Process for making 1,3-dioxane derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1989-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204455-A1 | Piperidine derivative rennin inhibitors | REN, ACE, HPN | HTR2C 2977/4885HTR2A 2480/4885HTR2B 1877/4885 |
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | HTR2C 1965/4885HTR2A 1537/4885HTR2B 2395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.